Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS)

Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against certain of its officers and directors for alleged breaches of fiduciary duty.

What Should Erasca Shareholders Do?

If you have held Erasca shares continuously since prior to January 14, 2025, you may have standing to seek corporate governance reforms at Erasca, including improvements to internal controls, transparency, and executive oversight.

You may also contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471. There is no cost or obligation to you.

Complaint Allegations

A previously filed securities complaint alleges, on April 27, 2026, Erasca disclosed that it had received a letter from Revolution Medicines alleging that ERAS-0015 infringed a Revolution Medicines patent, was connected to alleged trade-secret misappropriation, and had been improperly compared with Revolution Medicines’ RMC-6236 in public disclosures. The complaint further alleges that Erasca later reported preliminary Phase 1 clinical data for ERAS-0015, disclosed that a patient who received ERAS-0015 had died, and acknowledged that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and were inherently limited.